VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENTChange of Control and Severance Agreement • May 4th, 2022 • Veracyte, Inc. • Services-medical laboratories • California
This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between Ann (Annie) McGuire. (“Executive”) and Veracyte, Inc., a Delaware corporation (the “Company”), effective as of February 28, 2022 (the “Effective Date”).
April 20, 2022 Ms. Bonnie Anderson Delivered by hand or via email Dear Bonnie:Severance Agreement • May 4th, 2022 • Veracyte, Inc. • Services-medical laboratories • California
Veracyte, Inc. (the “Company”) is pleased to continue your employment as the Company’s Executive Chair (“Executive Chair”) on the terms set forth in this letter agreement (this “Agreement”), effective April 20, 2022 (the “Amendment Date”). This Agreement amends and restates in its entirety the letter agreement related to your service as Executive Chair by and between you and the Company dated May 28, 2021.
February 21, 2022Second Release • May 4th, 2022 • Veracyte, Inc. • Services-medical laboratories • Virginia
This letter confirms the agreement (“Agreement”) between you and Veracyte, Inc. (the “Company”) concerning the terms of your transition and separation from employment and offers you certain benefits to which you would not otherwise be entitled, conditioned upon your provision of a general release of claims and covenant not to sue now and upon the Separation Date (defined below) as provided herein. If you agree to the terms outlined herein, please sign and return this Agreement to me in the timeframe outlined below.
February 2, 2021 Tina S. Nova, PhD Delivered by hand or via email Dear Tina:Confidentiality Agreement • May 4th, 2022 • Veracyte, Inc. • Services-medical laboratories
As you may know, Veracyte, Inc. (the “Company” or “Veracyte”)1 is entering into an agreement with Decipher Biosciences, Inc. (“Decipher”) , pursuant to which the Company will acquire Decipher (the “Merger” and the closing thereof, the “Closing Date”). This offer is contingent on the closing of the Merger, and if you accept this offer of employment (this “Offer Letter”) would take effect as of the Closing Date (your “Veracyte Start Date”). You are critical to the Merger and it is a material condition to the Company’s willingness to complete the Merger that you enter into this Offer Letter.
